A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia | Zendy

Revanna Manjunatha | Zendy; H. P. Pundarikaksha | Zendy; HR Madhusudhana | Zendy; J Amarkumar | Zendy; BK Hanumantharaju | Zendy

Open Access

A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia

Author(s) -

Revanna Manjunatha,

H. P. Pundarikaksha,

HR Madhusudhana,

J Amarkumar,

BK Hanumantharaju

Publication year - 2016

Publication title -

indian journal of pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.286

H-Index - 59

eISSN - 1998-3751

pISSN - 0253-7613

DOI - 10.4103/0253-7613.178825

Subject(s) - silodosin , tamsulosin , alfuzosin , tolerability , medicine , urology , hyperplasia , open label , randomized controlled trial , pharmacology , adverse effect , lower urinary tract symptoms , prostate , cancer

Benign prostatic hyperplasia (BPH) is a common and progressive disease affecting elderly males, often associated with lower urinary tract symptoms (LUTS). α1-blockers are the mainstay in symptomatic therapy of BPH. Because of their greater uroselectivity and minimal hemodynamic effects, alfuzosin, tamsulosin, and silodosin are generally preferred. The aim of this study was to compare the efficacy and tolerability of alfuzosin, tamsulosin, and silodosin in patients with BPH and LUTS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research